- Home
- VIVK vs ACRV Comparison
VIVK vs ACRV Comparison
Compare VIVK & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVK
- ACRV
- Stock Information
- Founded
- VIVK 2006
- ACRV 2018
- Country
- VIVK United States
- ACRV United States
- Employees
- VIVK N/A
- ACRV N/A
- Industry
- VIVK Oilfield Services/Equipment
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- VIVK Energy
- ACRV Health Care
- Exchange
- VIVK Nasdaq
- ACRV Nasdaq
- Market Cap
- VIVK 34.5M
- ACRV 34.5M
- IPO Year
- VIVK N/A
- ACRV 2022
- Fundamental
- Price
- VIVK $0.87
- ACRV $1.31
- Analyst Decision
- VIVK
- ACRV Buy
- Analyst Count
- VIVK 0
- ACRV 7
- Target Price
- VIVK N/A
- ACRV $17.60
- AVG Volume (30 Days)
- VIVK 2.0M
- ACRV 466.7K
- Earning Date
- VIVK 08-15-2025
- ACRV 08-12-2025
- Dividend Yield
- VIVK N/A
- ACRV N/A
- EPS Growth
- VIVK N/A
- ACRV N/A
- EPS
- VIVK N/A
- ACRV N/A
- Revenue
- VIVK $111,130,140.00
- ACRV N/A
- Revenue This Year
- VIVK N/A
- ACRV N/A
- Revenue Next Year
- VIVK N/A
- ACRV N/A
- P/E Ratio
- VIVK N/A
- ACRV N/A
- Revenue Growth
- VIVK 85.84
- ACRV N/A
- 52 Week Low
- VIVK $0.55
- ACRV $1.05
- 52 Week High
- VIVK $3.45
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- VIVK 51.74
- ACRV 51.85
- Support Level
- VIVK $0.81
- ACRV $1.15
- Resistance Level
- VIVK $1.01
- ACRV $1.30
- Average True Range (ATR)
- VIVK 0.12
- ACRV 0.09
- MACD
- VIVK 0.01
- ACRV 0.03
- Stochastic Oscillator
- VIVK 58.99
- ACRV 61.54
About VIVK Vivakor Inc.
Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.